New Discovery About Cancer Target Wee1 Explains Drug Toxicity
“We think what’s happening in patients is that when they’re being treated with these Wee1 inhibitors, it’s stopping their normal fast proliferating cells, like you get in the colon and the blood system, from starting to replicate,” said Alexis Barr, head of the Cell Cycle Control group at the MRC Laboratory of Medical Sciences.
Scientists have discovered a previously overlooked weakness in certain cancer cells that could help researchers refine targeted treatments and reduce harmful side effects, scitechdaily.com reported. The study, published on October 21, 2026, in the journal Nature, reveals that the cancer drug target Wee1 also assists healthy cells in copying their DNA during an earlier stage of the cell cycle than previously recognized.
Key Clinical Takeaways:
- Researchers found that the enzyme Wee1 helps healthy cells begin copying DNA early in the cell cycle by regulating a protein degradation complex.
- Blocking Wee1 with cancer drugs can stall normal rapidly proliferating cells in tissues like the colon and blood system, which may explain current treatment toxicities.
- Understanding this newly identified mechanism could allow scientists to match Wee1 inhibitors more effectively to vulnerable tumors while sparing healthy tissue.
How Wee1 Protects Cancer Cells While Supporting Healthy Replication
Cancer cells that have lost one primary safeguard against DNA damage often become heavily dependent on a secondary safeguard: the enzyme Wee1. One of the human body’s main cellular safeguards is the tumor-suppressor protein p53, which typically halts the cell cycle when it detects DNA damage. In approximately half of all cancers, however, p53 is inactive, which allows damaged cells to continue growing unchecked. Under these conditions, Wee1 acts as a backup brake that prevents cells carrying damaged DNA from entering cell division. Cancers with mutated p53 rely heavily on this remaining safeguard, making Wee1 a major target for drug developers.
Despite this therapeutic rationale, drugs designed to block Wee1 have frequently triggered serious side effects in patients, disrupting clinical trials and threatening wider adoption in clinical settings. To investigate why these adverse events occur, researchers from the MRC Laboratory of Medical Sciences, the University of Oxford, and UCL examined the enzyme’s activity during the early stages of the cell cycle.
Challenging Established Mathematical Models of the Cell Cycle
Before conducting cell experiments, the research team built a mathematical model based on existing scientific literature to predict how healthy and cancerous cells would respond when Wee1 was inhibited. Because Wee1 had been studied primarily in the later stages of the cell cycle, the established literature failed to account for any early-stage functions.
“Wee1 has been very intensely studied in the later stages of the cell cycle, where targeting its activity for cancer treatment makes sense,” Alexis Barr stated. “However, the side effects of Wee1 inhibitors in patients were hard to explain based on these functions so we started to wonder if this Wee1 enzyme had some other function that we hadn’t appreciated that could explain these.”
When the team tested their mathematical predictions on laboratory cells, the results diverged sharply from the established literature. The experiments revealed that Wee1 helps healthy cells begin copying their DNA much earlier in the cell cycle by interacting with a protein degradation complex responsible for breaking down molecules needed for DNA replication. Normally, Wee1 helps switch off this complex so that replication can begin. Without sufficient Wee1 activity, the protein degradation complex remains active, which delays or entirely prevents cells from progressing through the cell cycle.
The findings published in the Nature study, titled “WEE1 opposes APC/CDH1 activity to promote S phase entry,” indicate that adverse clinical side effects stem from Wee1 inhibition halting normal, rapidly proliferating cells in the gastrointestinal tract and blood system. Funding for the research was provided by the Medical Research Council and Cancer Research UK.
By identifying this early role in cell cycle control, investigators hope to establish a precise therapeutic window. Cancers exhibiting reduced activity of the targeted protein degradation complex may prove particularly susceptible to Wee1 inhibitors, potentially allowing clinicians to administer lower doses that destroy tumor cells while minimizing damage to healthy tissues.
“We’re also starting to think about if there are different ways we could inhibit Wee1 that get round this early cell cycle function,” Alexis Barr noted, adding that exploring alternative inhibition methods remains a work in progress. The research team aims to test their mathematical and cellular predictions further in preclinical models as well as in patients currently enrolled in active Wee1 inhibitor clinical trials.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Keep reading